Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses early results of the Phase I/II BRUIN trial (NCT03740529) evaluating a next-generation, highly selective Bruton’s tyrosine kinase (BTK) inhibitor LOXO-305 in heavily treated patients with previously treated B-cell malignancies. The study included a large cohort of patients with various histological subtypes of B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldernström’s macroglobulinemia (WM), diffuse large B-cell lymphoma (DLBL), and marginal zone lymphoma (MZL). The analysis showed good overall response rates (ORR) across a range of B-cell malignancies. Additionally, LOXO-305 showed a good safety profile with minimal serious adverse events across cohorts. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.